# The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities

## TL;DR

The NLRP3 inflammasome is a key immune system component involved in inflammation and disease, with new therapeutic strategies being explored.

## Contribution

The paper provides updated insights into NLRP3 mechanisms and highlights third-generation therapeutic approaches for precision treatment.

## Key findings

- NLRP3 activation is linked to various diseases, including autoinflammatory and neurodegenerative conditions.
- New therapeutic strategies include allosteric inhibitors and biologics targeting NLRP3.
- Mechanistic insights enable precision matching of compounds to patient contexts.

## Abstract

The NLRP3 inflammasome is a pivotal signaling platform of the innate immune system that senses a broad spectrum of microbial, metabolic, and environmental danger signals. Its activation leads to the recruitment of ASC and caspase‐1, driving the maturation of pro‐inflammatory cytokines interleukin (IL)‐1β and IL‐18 as well as the execution of pyroptosis. Aberrant or persistent activation of NLRP3 has been implicated in the pathogenesis of numerous disorders, including autoinflammatory syndromes, metabolic and cardiovascular diseases, neurodegenerative conditions, and cancers. In this review, we provide an updated overview of the molecular mechanisms governing NLRP3 activation and regulation, with particular focus on ion flux, mitochondrial damage, lysosomal rupture, reactive oxygen species, and post‐translational modifications. We further discuss negative regulatory pathways that maintain inflammasome homeostasis and prevent excessive inflammation. Finally, we summarize recent advances in therapeutic strategies targeting the NLRP3 inflammasome, ranging from direct inhibitors and allosteric modulators to biologics and repurposed drugs, and highlight their translational potential. Understanding the fine balance between NLRP3 activation and inhibition offers new opportunities for therapeutic intervention in a wide array of inflammatory and immune‐related diseases.

Diverse diseases converge on NLRP3. We depict a discovery‐to‐clinic track: high‐throughput/phenotypic screens, structure‐guided design, and modality innovation (allosteric inhibitors, interface blockers, degraders) deliver third‐generation, disease‐tailored NLRP3 control. Mechanistic insights into activation and regulation map druggable nodes to indications, enabling precision matching of compounds to patient contexts.